Joseph Nates, MBA, MD

Professor, Deputy Chair, Director ICUs
University of Texas MD Anderson Center
Bellaire, Texas, United States

Joseph L. Nates, MD MBA CMQ MCCM, Deputy Chair of the Critical Care Department, Division of Anesthesiology and Critical Care, Medical Director of the Oncologic Intensive Care Units (SICU and MICU) of The University of Texas MD Anderson Cancer Center. President of the Oncologic Critical Care Research Network (ONCCC-R-NET). He is the Scientific Director of the Iberic and Pan American Federation of Critical Care Societies (FEPIMCTI). He is also Editor of "Oncologic Critical Care" textbook, the first comprehensive treatise on the subject in English, and "Oncología Crítica", the first comprehensive textbook about the subject in Spanish. Dr. Nates led the first two international oncologic critical care symposiums in the country. Dr. Nates is considered a pioneer in the field of oncologic critical care.

Disclosure information not submitted.

Presentation(s):

• A Descriptive Study of Vasopressor Titration in Medical ICU Patients With Septic Shock

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• A Meta-Analysis Evaluating Outcomes of Critically Ill Cancer Patients by Geographical Region

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• A Multidisciplinary Approach to Reduce Opioid Use in Mechanically Ventilated Solid Cancer Patients

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• A Systematic Review Evaluating Mortality in Critically Ill Cancer Patients With Sepsis

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Clinical Characteristics of COVID-19 in Oncology Patients: Case-Control Design: Pilot Study

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Comparative Outcomes of Acute Kidney Injury in Critically ill Patients With COVID-19 Infection

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Comparative Outcomes of COVID-19 Survivors Versus Nonsurvivors in an Academic Intensive Care Unit

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Effects of Recent Use of Checkpoint Inhibitors on Outcomes of Cancer Patients With Septic Shock

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• End-of-Life Care and Clinical Characteristics of Nonsurvivor Cancer Patients With COVID-19

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Factors Associated With Mortality in Patients With Hematologic Malignancies and Septic Shock

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Hypophysitis and Pneumonitis Secondary to Checkpoint Inhibitor Combination Therapy: A Case Report

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Immune Checkpoint Inhibitor-Induced Overlap Syndrome: A Case Series

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Outcomes of Acute Kidney Injury in Hematologic Cancer Patients With Septic Shock

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Outcomes of Critically Ill Patients With Acute Leukemia and Septic Shock

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Performance of an Automated Deterioration Index as an Early Warning System for ICU Outreach

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Risk Factors of Short-Term Mortality in Patients With Septic Shock and Solid Tumors

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Septic Shock Mortality Reported in Clinical Trials in the Last Decade: A Systematic Review

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST

• Systematic Review and Meta-Analysis of Mortality in Cancer Patients Treated in Intensive Care Units

  Monday, April 18, 2022
  7:00 AM – 8:00 AM US CST